Results 161 to 170 of about 108,435 (311)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Intravenous Immunoglobulin Efficacy and Safety in Paediatric Patients Diagnosed with Acute Myocarditis. [PDF]

J Clin Med
Sorescu AM, Coman OA, Raoul-Vasile L, Duica G, Alin N, Cinteză EE, Ion F, Ghiță CIV.   +7 more
europepmc   +1 more source

Quantification of human intravenous immunoglobulin from plasma and in process samples by affinity chromatography

Markus Mozgovicz, Nico Lingg, Igor Tadeu Lazzarotto Bresolin, Theresa Schaufler, Alois Jungbauer   +4 more
openalex   +1 more source

The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia

, 2021
Ali Almontasheri, Faisal Al-Husayni, Anas Alsuraihi, Hanan Binyahib, Amr S. Albanna   +4 more
openalex   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

HOME INTRAVENOUS IMMUNOGLOBULIN THERAPY

The Lancet, 1988
Chapel, H, Brennan, V
openaire   +3 more sources

Direct Medical Costs of Liquid Intravenous Immunoglobulins in Children, Adolescents, and Adults in Spain [PDF]

, 2011
Josep Darbà, G Restovic, Lisette Kaskens, T de Agustin   +3 more
openalex   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source

Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report. [PDF]

BMC Neurol
Hu BQ, Wu SX, Tong QW, Ye H, Jin PP.
europepmc   +1 more source